Rehabilitation measures meaningful daily improvements

Trial ID
NCT06487364
Official Title
Determination of the Minimal Detectable Change and Minimum Clinically Important Change Score of the Parkinson's Disease Questionnaire-8
Goal
Rehabilitation measures meaningful daily improvements
Status
RECRUITING
Sponsor
Emre Şenocak
Study Type
OBSERVATIONAL
Enrollment
39 participants
Conditions
Parkinson Disease
Interventions
Rehabilitation

Plain-Language Summary

The goal is to figure out how much change in the PDQ-8 quality of life score counts as a real, measurable difference and as a meaningful improvement for people with Parkinson's. Participants will take part in a rehabilitation program and complete the PDQ-8 before and after treatment, so researchers can calculate the minimal detectable change and the minimum clinically important change, with the PDQ-8 measuring Parkinson's-related daily life and wellbeing. The study is looking for people aged 40 to 80 with mild to moderate Parkinson's (Hoehn and Yahr stages 1,3), on stable Parkinson's medications with regular neurology follow-up, normal cognition (MMSE >24), and without other neurological disease, recent upper limb surgery or ongoing pain, active mood disorders, substance use, or uncorrectable vision or hearing loss.

Locations

  • Private Güney Hospital, Istanbul, Turkey (Türkiye)

Frequently Asked Questions

What is this trial testing?
This trial is studying Rehabilitation. The goal is to figure out how much change in the PDQ-8 quality of life score counts as a real, measurable difference and as a meaningful improvement for people with Parkinson's. Participants will take part in a rehabilitation program and complete the PDQ-8 before and after treatment, so researchers can calculate the minimal detectable change and the minimum clinically important change, with the PDQ-8 measuring Parkinson's-related daily life and wellbeing. The study is looking for people aged 40 to 80 with mild to moderate Parkinson's (Hoehn and Yahr stages 1,3), on stable Parkinson's medications with regular neurology follow-up, normal cognition (MMSE >24), and without other neurological disease, recent upper limb surgery or ongoing pain, active mood disorders, substance use, or uncorrectable vision or hearing loss.
Who can participate?
Participants must be between 40 Years and 80 Years.
Where is this trial located?
This trial is recruiting at 1 location.
Does it cost anything to join?
No. There is no cost to participate. Study-related care and treatment are provided at no charge.
How long does the trial last?
This trial is estimated to last approximately 8 months.

View on ClinicalTrials.gov